A judge has signed off on almost $7.5 million in fees billed by the law firm behind the pelvic mesh class action against Boston Scientific, eight months after he approved the device maker’s $105 million settlement.
Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.
A judge has upheld a ruling that rejected a bid by two class actions against Victorian aged care providers for insurance and financial information, finding the court likely does not have the power to order the production of documents that are not relevant to the proceeding.
South Korean biosimilars company Samsung Bioepis has sued to invalidate two patents held by a German competitor for a pre-filled syringe to treat age-related eye diseases, as generic drug makers race for a piece of the lucrative eye drug market.
An investigation is underway against US medical device maker Exactech on behalf of patients who allegedly received faulty hip, knee or ankle implants.
The Office of the Australian Information Commissioner has brought civil penalty proceedings accusing pathology services provider Australian Clinical Labs of failing to take steps to prevent a February 2022 data breach that affected millions of patients.
Novartis unit Sandoz AG has lost its bid to revoke Bayer’s patents for its top-selling blood clot drug Xarelto and has been barred from selling generic versions of the medication after a judge found the German pharma giant’s patents were valid.
Two more Victorian healthcare providers have been hit with a class action on behalf of junior doctors alleging they were not paid for unrostered work.
The digitisation of healthcare has left the industry particularly vulnerable to cyberattacks, and protecting consumers from breaches is one of the biggest challenges facing the sector, according to a new health law partner at Wotton + Kearney.
A judge has questioned a challenge by two class actions against Victorian aged care providers to a ruling that rejected their bid for insurance and financial information, which the defendants argue would have far-reaching implications.